Moderna reports vaccine remains highly effective through six months
Moderna Inc. today announced during an investors report that its COVID-19 vaccine remains 93% effective through the first six months following a full dosing regimen.
Moderna also reported that, in its effort to earn full Food and Drug Administration approval for the vaccine, it initiated the rolling submission process for a Biologics License Application for the current vaccine in the U.S., a process it expects to complete its submission in August. Moderna also has completed enrollment for a phase 1 clinical trial of a next-generation COVID-19 vaccine that will be refrigerator-stable.
Related News Articles
Headline
The Food and Drug Administration yesterday published an announcement from Otsuka ICU Medical saying that the company issued a voluntary recall for a mislabeled…
Headline
A study published Oct. 30 by the American Heart Association found that people have an elevated risk of heart attack and stroke following flu and COVID-19…
Headline
The Centers for Disease Control and Prevention will update its immunization schedules for the COVID-19 and chickenpox vaccines to adopt recent recommendations…
Headline
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…
Headline
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…